Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase NA × Carcinoma, Hepatocellular × Lenalidomide × Clear all

Phase

Phase NA 1 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Multiple Myeloma 3 Recurrence 1 Neoplasms, Plasma Cell 1 Neoplasm, Residual 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Leukemia, Myeloid, Acute 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Carcinoma, Hepatocellular 1 Amyloidosis 1

Interventions

Radiosurgery 17 lenvatinib 15 Radiofrequency Ablation 13 Hepatectomy 12 Sorafenib 10 Surgical Procedures, Operative 7 Magnetic Resonance Spectroscopy 7 camrelizumab 6 Radiotherapy 6 Immune Checkpoint Inhibitors 6 Blood Specimen Collection 6 apatinib 5 Electroporation 5 Bevacizumab 5 sintilimab 4 Yttrium-90 4 Proton Therapy 4 Oxaliplatin 4 Liver Transplantation 4 Doxorubicin 4 Catheter Ablation 4 tislelizumab 3 spartalizumab 3 atezolizumab 3 X-Rays 3 Standard of Care 3 Injections 3 Heavy Ion Radiotherapy 3 Fluorouracil 3 Embolization, Therapeutic 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07184424 2025-09-19

Lenalidomide

Beijing Tsinghua Chang Gung Hospital

Phase NA Completed

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡